Image: E. coli by S. Schuller. Attribution 4.0 International – CC BY 4.0Annual Reports
We are pleased to report on the Clinical Infection Research Group’s activity which goes from strength to strength
OUR ANNUAL REPORTS
2024-2025
2024-2025
The past year, CIRG led 19 active infectious disease studies, recruiting over 230 participants and expanding its academic and commercial research portfolio.
CIRG strengthened partnerships with the Fleming Fund, Roslin Institute, Anne Rowling Clinic, and the Centre for Homelessness and Inclusion Health, contributing to research in antimicrobial resistance, neurological conditions, and healthcare for vulnerable populations.
We are very proud of the innovative work our members are a part of and that work is being recognised at conferences across the country. The CIRG Awards continued to support staff to attend conference and produce publications of their work.
2023-2024
2023-2024
CIRG has had a diverse and productive year between August 2023-24, building relationships in academia and industry and broadening our infectious diseases research experience.
We currently have 25 active clinical studies involving 14 different PIs and sub-PIs. This year has also brought other exciting opportunities for CIRG both locally and internationally. EID partners closely with the Fleming Fund and we are further strengthening relations with EID through mentoring Fleming fellows in Africa.
Finally, we are very proud of the significant CIRG presence at the Federation of Infection Societies in Edinburgh 2023 with multiple oral and poster presentations from CIRG members.
2022-2023
2022-2023
August 2022 – August 2023 has been a busy year having finally emerged from the COVID-19 pandemic. Our portfolio continues to be dominated by COVID trials, vaccine studies, and therapeutic work of both pre-hospital and hospitalised patients.
However, we also continue to contribute to our longstanding HIV cohort studies and in addition are now involved in exciting novel immunological therapies for HIV – which may lead the way to curative therapies in the future.
We are also delighted to be part of other microbiological studies including managing necrotizing otitis externa, eradication of MRSA, and optimising management of staphylococcus aureus bacteraemia.
ANY QUESTIONS?
If you have any questions about our research, or if you’d like to get involved with CIRG, contact us.
